LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced the signing of a definitive co-promotion agreement for Perforomist™ (formoterol fumarate) Inhalation Solution (Perforomist) with Dey, L.P. (DEY). The definitive agreement supersedes the binding letter agreement that the two companies entered into on March 13, 2007. In May 2007, the U.S. Food and Drug Administration (FDA) approved DEY’s new drug application for Perforomist for the long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).
